Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.55 |
| ▸ | JAK2 | O60674 | 8/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | YES1 | P07947 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17135682 | 0.93 | SYK (0.53) | SYKJAK2HTR2AHTR2CJAK3 | |
| SCHEMBL14320440 | 0.91 | JAK2 (0.55) | SYKJAK2HTR2AHTR2CABL1 | |
| SCHEMBL14320283 | 0.89 | SYK (0.58) | SYKJAK2HTR2AHTR2CABL1 | |
| SCHEMBL14320292 | 0.88 | SYK (0.54) | SYKJAK2HTR2AHTR2CABL1 | |
| SCHEMBL14320458 | 0.86 | SYK (0.57) | SYKJAK2HTR2AHTR2C | |
| SCHEMBL14320599 | 0.86 | SYK (0.53) | SYKJAK2HTR2AHTR2CABL1 | |
| SCHEMBL14321127 | 0.82 | JAK2 (0.61) | SYKJAK2HTR2AHTR2CPDGFRB | |
| SCHEMBL14320971 | 0.81 | SYK (0.53) | SYKJAK2ABCG2 | |
| SCHEMBL14320671 | 0.80 | JAK2 (0.57) | SYKJAK2HTR2AHTR2CMAPK1 | |
| SCHEMBL14320547 | 0.80 | GRM5 (0.52) | SYKJAK2ABL1KDRABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | claimed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | claimed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | claimed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | SYK 11/4885JAK2 60/4885HTR2A 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.